Phase 4
N=87
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT02020512 ↗Enrolled (actual)
87
Serious AEs
0.0%
Results posted
Jul 2014
Primary outcome: Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.2; -6.7 Millimeters of Mercury (mmHg)
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- 0.03% Bimatoprost (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Dec 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Intraocular Pressure (IOP) in the Study Eye |
22.2; -6.7 | — |
Summary
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of open-angle glaucoma or ocular hypertension
- No use of Lumigan® in the past 3 months
Exclusion Criteria
- Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months
Data sourced from ClinicalTrials.gov (NCT02020512). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.